Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Active not recruiting 3

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other solid neoplasm 3

Conditions

Leukemia, Myeloid, Acute 49Neoplasm Metastasis 47Multiple Myeloma 40Breast Neoplasms 33Prostatic Neoplasms 31Colorectal Neoplasms 27Lymphoma 26Lung Neoplasms 26Leukemia, Lymphocytic, Chronic, B-Cell 24Pancreatic Neoplasms 22Myelodysplastic Syndromes 22Lymphoma, Large B-Cell, Diffuse 21Triple Negative Breast Neoplasms 19Ovarian Neoplasms 17Melanoma 17Carcinoma, Non-Small-Cell Lung 17Burkitt Lymphoma 17Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Carcinoma, Renal Cell 15Neoplasms 14Leukemia, Myelomonocytic, Chronic 13Glioma 13Neuroblastoma 12Lymphoma, Mantle-Cell 12Lymphoma, Follicular 12Sarcoma 11Lymphoma, Non-Hodgkin 11Fallopian Tube Neoplasms 11Endometrial Neoplasms 11Myeloproliferative Disorders 10

Interventions

Specimen Handling 7Interviews as Topic 4Standard of Care 3Practice Guidelines as Topic 3Biopsy 3X-Rays 2Methods 2Educational Status 2Early Intervention, Educational 2trastuzumab biosimilar HLX02 1pertuzumab 1erdafitinib 1copanlisib 1Verteporfin 1Trastuzumab 1Palliative Care 1PF-05280014 1Ontruzant 1Ogivri 1Magnetic Resonance Spectroscopy 1Iohexol 1Health Promotion 1Exercise Test 1Carboplatin 1CT-P6 1Asian ginseng 1Art Therapy 12C4 antibody 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Malignant Solid Neoplasm × Biopsy × 1 year × Clear all
NCT06136897 2026-05-29

Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
35 enrolled 10 charts
Other solid neoplasm

Malignant Solid Neoplasm

NCT06351371 2026-05-28

Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Mutations or Fusions (MATCH - Subprotocol K2)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
35 enrolled 10 charts
Other solid neoplasm

Malignant Solid Neoplasm

NCT06360588 2026-05-28

Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Loss (MATCH - Subprotocol Z1G)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
22 enrolled 9 charts
Other solid neoplasm

Malignant Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡